← Back to Search

Live Remote Cardiac Monitoring for Fainting (REMOSYNC Trial)

N/A
Waitlist Available
Led By Venkatesh Thiruganasambandamoorthy, MBBS
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 days
Awards & highlights

REMOSYNC Trial Summary

This trial will compare the diagnostic yield of two strategies for detecting serious arrhythmias among high-risk ED syncope patients who are discharged home.

Eligible Conditions
  • Fainting
  • Arrhythmia

REMOSYNC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15-days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15-days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants among whom arrhythmias are detected that required treatment
Secondary outcome measures
Compliance of the participants in wearing the devices
Detection of arrhythmias that did not require treatment
Exclusion of arrhythmia
+1 more

REMOSYNC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Live Remote Cardiac MonitoringExperimental Treatment1 Intervention
Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
Group II: Usual CareActive Control1 Intervention
Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiophone
2016
N/A
~100

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,592 Total Patients Enrolled
Venkatesh Thiruganasambandamoorthy, MBBSPrincipal InvestigatorOttawa Hospital Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings for participants in this clinical experiment?

"According to the clinicaltrials.gov database, this study is no longer accepting patients as it was last updated on October 30th 2020. However, there are currently 253 other trials who have open enrollment and are recruiting participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients After Discharge - A Pilot Study
2016. "Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients After Discharge - A Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02786940.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top